Berlin

The Proteome Factory AG is a modern biotech company. Scientific research focuses on neurodegenerative disease and oncology. The proteomic key technology platform enables key proteins in emerging disease and biomarkers for the disease state to be rapidly and efficiently identified. Target proteins are then validated, initially through the use of virally and stably transfected cell lines and, at a later stage, transgenic and knock-out technologies are applied. This combination of validatory techniques enables the Proteome Factory AG to distinguish more relevant target proteins for a specific disease process, highlighting possible therapeutic targets. The main task of the Proteome Factory AG therefore is the development and validation of new therapeutic drugs with a particular focus on neurodegenerative disease and cancer.

Bremen

A global company focused on the advancement of all of the sciences supported by mass spectrometry, with a commitment to finding new and more powerful uses of MS technology wherever possible. Supplies the PROTEUM Series of products which is focused on the determination of crystallographic structures of proteins and other biological macromolecules. Don't forget, Bruker Daltonik Germany has a terrific website.

Freiburg

Matritech is a leading developer of proteomics-based diagnostic products for the early detection of cancer. Using its patented proteomics technology, Matritech has identified proteins correlated with breast, bladder, prostate, cervical and colon cancers. Matritech is one of the first companies to successfully employ proteomics to create diagnostic products. The company holds one of only two FDA product approvals for the initial detection of cancer. The FDA-approved NMP22 bladder cancer test is currently used by urologists. In addition, the company has a promising blood-based breast cancer test, NMP66, in clinical trials. Initial research on a prostate cancer marker identified by Matritech scientists shows the maker to be more accurate than the widely-used PSA test. NMP technology was licensed exclusively to Matritech from the Massachusetts Institute of Technology.

Heidelberg

Cellzome, a leader in the field of functional proteomics, uses its proprietary technology platform to characterize cellular protein complexes. Protein complexes are responsible for biological activity and are the actual molecular targets of drugs. Cellzome is developing protein interaction and pathway maps obtained under varying experimental conditions. This information will describe the molecular context for identified targets and provide the basis for target and lead validation. Cellzome believes that this approach will enable better understanding of the mode of action of existing and potential drugs, creating the opportunity to develop second generation drugs with higher efficacy, specificity and safety profile.

Hennigsdorf

EUROPROTEOME applies state-of-the-art, convergent gene expression technologies - in particular proteomics and transcriptomics to human epithelial cancers (e.g. colon or lung cancer) in order to identify cancer-specific protein expression patterns (targets / markers) suited for clinical applications. After characterizing and validating these identified targets, EUROPROTEOME offers these targets for co-development agreements with industrial clients and marketing partners.

Magdeburg

MelTec is a pioneer in topological proteomics optimising the drug discovery process in the post-genomic era. MelTec represents the only company with a proprietary technology capable of performing completely automated proteomics characterization at the single cell level, for an unlimited number of proteins. The company's approach aims to understand and decipher cellular function and dysfunction by determining the situation of protein networks in time and space in every intact cell. MelTec's topological proteomics technology facilitates and greatly speeds the pre-clinical stages in the drug development process and the identification of biomarkers for diagnostic purposes. MelTec's unique proteomics technology positions the company to become a major contributor to this new post-genomics era of drug development.

Martinsried

Biomax Informatics AG and Roche announce ProteoExpert speeds up protein research. ProteoExpert RTS E. coli HY is a new Internet-based information service from Roche Diagnostics. It's designed to assist scientists working in the field of protein research with the Rapid Translation System (RTS), Roche's platform for cell-free protein synthesis. The ProteoExpert was developed in co-operation with Biomax Informatics AG, Martinsried, Germany and will reduce costs and add considerable efficiencies to cell-free protein synthesis.

Munich

GeneData is a global leader in the development of bioinformatics systems and related services in the functional genomics arena. We deliver innovative computational solutions for the management and intelligent analysis of large quantities of structurally complex biological data, generated by genome sequencing, microarrays, protein expression profiling, metabolic profiling and high-throughput screening. Our partners include major life-sciences organizations and some of the world's most prestigious research institutions. We strive to help our partners maximize their return on investment from costly technologies and gain a deeper understanding of underlying biological processes for advancement of their own research and product development. Founded in 1997, GeneData has grown to a team of around 70 experts from diverse fields including molecular biology, biochemistry, computer science, (bio)physics, mathematics and statistics. Our growth continues as we recruit the best people for developing and applying in-silico methods for functional genomics problems.

Xerion Pharmaceuticals (founded in 1998) is a functional proteomics company located in Martinsried/Munich, one of Europe's hottest biotech clusters. The combination of our powerful vision, corporate culture, smart and energized people, and innovative technology make us stand out against others. Xerion provides viable and profitable drug development solutions. Xerion focuses on proteins, the molecules that perform most biological functions and represent the vast majority of today's and tomorrow's drug targets. The Company has assembled and combined unique and effective technologies for drug target identification (Xcelerate™), validation (XCALIbur™) and functional site identification (X-plore™). The core technology of the platform is XCALIbur™, a proprietary method for specific functional analysis of proteins which Xerion has established as a target validation tool. This centerpiece is complemented by combinatorial biology and mass spectrometry for target and functional site identification. These technologies optimize critical steps in the drug development process to provide valuable solutions in the search for novel, safe and therapeutic drugs. This makes us a technology leader in functional proteomics.

Teltow

WITA Proteomics is dedicated to providing complete proteomics solutions to partners interested in understanding the identity and potential role of proteins from a specific cellular source under particular conditions. Our position as a leading partner for ultra high-resolution proteomics, our High Performance Proteomics™, analysis is demonstrated by the meaningful results we deliver to our partners. WITA's High Performance Proteomics™ platform provides unparalleled spot resolution, up to 10,000 protein spots per gel, a greater then 5 fold advantage over competing methodologies. In conjunction with Sypro Ruby™ staining we offer the most sensitive protein detection and identification solution available. WITA differentiates itself from a number of proteomics companies in that it goes beyond the process of identifying proteins, their modifications, sequence analysis and database compilation and licensing. In addition to delivering these data we deliver an analysis of the biochemical implication of the presence of modified proteins, and the strategic use of such information for drug development as well as for diagnostic use.

Tubingen

Tubingen Univeristy Proteome Lab

Waldbronn

Life Sciences/Chemical Agilent is a leading provider of life sciences and analytical instrument systems to scientists in life sciences, pharmaceutical, environmental and chemical industries, worldwide. The company offers scientists the range of instruments, systems and services needed for success in acquiring and interpreting genetic and chemical information - from sample handling, to analysis to data management and reporting. We are committed to providing superior standards-based technology, designed for maximum productivity, cost effectiviness and ease in complying with regulatory requirements. Through lab-on-a-chip technology the 2100 bioanalyzer integrates sample handling, separation, detection and data analysis onto one platform. It moves labs beyond messy, time consuming gel preparation and the subjective results associated with electrophoresis. And now, with our second generation 2100 bioanalyzer, we have integrated an easier way to acquire cell based parameters from as few as 20,000 cells per sample.